| |
Wednesday, September 11, 2024 | 2pm ET / 11am PT As the drug development landscape rapidly evolves, artificial intelligence (AI) is emerging as a transformative force, fundamentally reshaping processes and enhancing efficiencies. Join us for a deep dive into AI’s significant impact on streamlining clinical project management, revolutionizing the generation of crucial research outputs and accelerating drug discovery. Register now.
|
|
Today’s Big NewsAug 7, 2024 |
|
Cell therapy developers face many challenges as they transition from benchtop to bedside. Here we examine when and how to consider transitioning from research-use-only to animal-free (AF) and GMP critical reagents. Download now.
|
|
| By Gabrielle Masson Fierce Biotech’s Gabrielle Masson was on the New York Stock Exchange floor this morning to present the 2024 class of Fierce 15 on NYSE TV. Check out Gabrielle’s interview here and the full Fierce 15 list here! |
|
|
|
By Fraiser Kansteiner With supplies of its star obesity med Wegovy now largely unfettered, Novo Nordisk is dialing up its sales expectations for the remainder of the year—and teasing the potential for net price declines on the immensely popular GLP-1. |
By Annalee Armstrong Stoke Therapeutics’ Dravet syndrome drug has been freed from a partial hold, clearing the way for the construction of a phase 3 program. |
By Andrea Park Genentech and the American Diabetes Association have a vision of a world with more equitable access to eye health care for all people with diabetes. |
|
Dive into the cutting-edge world of recombinant antibody engineering, from optimizing your antibody plasmid to antibody maturation and humanization. Explore innovative techniques and strategies that enhance antibody efficacy, paving the way for breakthroughs in therapeutic development. Download now.
|
|
By Heather Landi Medical device makers Abbott and Medtronic unveiled a global partnership that pairs Abbott's continuous glucose monitoring (CGM) sensors with the Medtronic insulin delivery system. |
By Fraiser Kansteiner After a rocky start to the year, Merck KGaA’s CDMO and process solutions units appear to be nearing a comeback. |
By Nick Paul Taylor Novo Nordisk has axed its once-monthly dual GLP-1/GIP receptor agonist, ending development of a drug candidate that it singled out as an exciting part of its pipeline earlier this year. |
By Ben Adams From sounding like a companion of Thor speciality biopharma Aeterna Zentaris is no more: Meet COSCIENS Biopharma. |
By Nick Thomas Diality, a Californian renal device maker, has received FDA 510(k) clearance to help market its new hemodialysis product. |
By Angus Liu Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer. |
By Annalee Armstrong Fierce Biotech Associate Editor Gabrielle Masson presented the 2024 class of Fierce 15 winners on the floor of the New York Stock Exchange on Wednesday. |
By Nick Paul Taylor Ogilvy Health has promoted Shannon Walsh to the newly created role of chief operating officer (COO). The position gives Walsh oversight of agency operations, marketing, communications and innovation for North America. |
By Nick Thomas The integration of Alara's software supports compliance with new Hospital Quality Reporting electronic clinical quality measures (eCQMs). |
By Kevin Dunleavy Amgen’s roller coaster ride known as Tepezza is ascending again. Is the thyroid eye disease treatment finally gaining momentum that is sustainable? In the second quarter, Tepezza generated $479 million in sales for an increase of 8% year over year and 13% sequentially. It was Tepezza’s highest quarterly sales figure since the fourth quarter of 2022. |
By Darren Incorvaia Primarily a respiratory virus, our understanding of SARS-CoV-2 has been hampered by an inability to study the pathogen in its natural habitat—a living, breathing human lung. Thankfully, lung biologist Sandra Leibel, M.D., has been working with “mini-lungs” derived from human stem cells since 2012. |
By Zoey Becker The university accused Pfizer's Comirnaty partner of failing to pay the full total of royalties owed on worldwide product sales through a sublicense agreement to Penn's mRNA patents. |
Fierce podcastsDon’t miss an episode |
| This week on “The Top Line,” we dive into two studies in HIV research that were presented at the 25th International AIDS Conference in Germany. |
|
|---|
|
|
| WhitepaperThis paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs. Sponsored by: AIM |
| WhitepaperDownload the white paper to learn how this innovative solution can help optimize your mAb production processes. The findings demonstrate the system's robust capability to sustain strong cell growth and high productivity, facilitating a smooth transition from laboratory to production scale. Sponsored by: Thermo Fisher Scientific |
| WhitepaperThe definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond. Sponsored by: AVANT BIO |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
